A B S T R A C T
Background. Patients with immunoglobulin A nephropathy (IgAN) who present with mild to moderate proteinuria and normal renal function are assumed to have excellent short-term renal prognosis, but the long-term prognosis is uncertain. Methods. Patients were selected from the Norwegian Kidney Biopsy Registry based on the following criteria: diagnostic renal biopsy performed in the period 1988-99, with estimated glomerular filtration rate (eGFR) !60 mL/min/1.73 m 2 and proteinuria <1 g/24 h at the time of biopsy. Patients were invited for a nephrological examination with a review of medical history and investigation of blood pressure, urinary findings and eGFR. Results. A total of 145 patients attended the examination, performed by the first author, after a median of 22 (interquartile range [19] [20] [21] [22] [23] [24] [25] years after diagnosis. At the examination, 27 patients (18.6%) had a !50% decrease in GFR, of whom 4 (2.8%) had developed end-stage renal disease (ESRD). The mean duration from renal biopsy to ! 50% decrease in GFR was 17.3 6 5.1 years in our cohort. Clinical remission was observed in 42 (29.0%) patients. Renal biopsies were re-examined utilizing the Oxford classification criteria. Mesangial hypercellularity was found in 12.3%, endocapillary proliferation was detected in 10.7% and segmental glomerulosclerosis was observed in 23.8%. All biopsies were scored as T0 (tubular atrophy in < 25% of the cortical area). None of the clinical or histopathological variables recorded at the time of biopsy could identify patients with progressive disease. Cumulative risks of !50% decrease in eGFR were 2.1% after 10 years, 4.1% after 15 years, 13.9% after 20 years and 24.7% after 25 years. Conclusions. We have shown that 18.6% of patients with assumed benign IgAN had progressive disease after a median duration of 22 years and that these patients could not be predicted at the time of biopsy. Our study demonstrates that an extended follow-up period is needed when assessing prognosis in this group of patients.
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I N T R O D U C T I O N
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis and an important cause of endstage renal disease (ESRD) [1] [2] [3] . Frequent clinical manifestations of IgAN are asymptomatic haematuria and proteinuria or episodes of macroscopic haematuria often following an upper respiratory tract infection. Long-term outcome in patients with IgAN is highly variable and ranges from remission of urinary abnormalities with preserved kidney function to progressive kidney damage and ESRD [4] [5] [6] . Several prognostic factors for renal survival at the time of diagnosis have been recognized, the most important of which are estimated glomerular filtration rate (eGFR), proteinuria, hypertension and histopathological changes [5] [6] [7] [8] [9] [10] . IgAN patients with normal-range eGFR and proteinuria of <1 g/24 h are usually considered to have an excellent prognosis [5, 7, 8, 10, 11] . In general, recent prognostic studies in IgAN have found improved prognostic capacity by applying the Oxford/MEST (mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis and tubular atrophy/interstitial fibrosis) classification to evaluate histopathological findings in IgAN [12] [13] [14] ; however, whether this novel system offers an enhanced value in predicting patients with clinical mild disease seems uncertain.
The diagnosis of IgAN requires a kidney biopsy, but the current nephrology practice in many countries is not to perform 
this invasive procedure in patients with isolated microscopic haematuria and/or low-grade proteinuria and normal eGFR [11, 15] . Consequently, assumed benign IgAN is often likely to remain undiagnosed. In countries with a more liberal biopsy policy, more IgAN patients with isolated haematuria and/or low-grade proteinuria are diagnosed, and several studies from Asian countries have shown that these patients do not always have a favourable prognosis [16] [17] [18] [19] [20] . One study from Spain showed that patients with proteinuria <0.5 g/24 h and normal eGFR had an excellent prognosis [11] . Genetic differences, differences in the definition of endpoints and lead-time bias due to divergence in biopsy policy may be plausible explanations for the discrepant results between the European and Asian studies [4, 21, 22 ]. An important finding in earlier studies is that a prolonged observation period is needed to identify progressive cases among patients with assumed benign IgAN.
Previously, Norwegian nephrologists tended to perform a renal biopsy on patients with microscopic or macroscopic haematuria and low-grade proteinuria, and more cases with presumed stable IgAN were thus diagnosed. Since 1988, all of these patients have been registered in the Norwegian Kidney Biopsy Registry (NKBR). In the present study we investigated the longterm outcome in patients with IgAN diagnosed between 1988 and 1999 who at the time of biopsy had proteinuria <1 g/24 h and eGFR >60 mL/min/1.73 m 2 . Our hypothesis was that longterm prognosis is not always favourable, and we wanted to investigate prognostic markers, including the predictive value of the MEST score, in these patients.
M A T E R I A L S A N D M E T H O D S
The study was approved by the regional ethics committee and conducted in accordance with the principles of the Declaration of Helsinki.
Patient selection
The NKBR has registered clinical and histopathologic data for almost all patients with a kidney biopsy in Norway since April 1988. The responsible physicians report clinical data in a registry notification form. The nephropathologic unit in the pathology department at Haukeland University Hospital reported histopathology data after a thorough examination of the kidney biopsies, providing a consistent diagnosis in all patients.
Patients registered with primary IgAN in the NKBR between April 1988 and December 1999 with proteinuria <1 g/24 h and eGFR !60 mL/min/1.73 m 2 at the time of biopsy were identified. Only patients diagnosed in the Department of Pathology at Haukeland University Hospital were selected and those with Henoch-Schönlein purpura, diabetes, liver disease, systemic disease or any type of secondary disease were excluded. A total of 192 patients fulfilled the inclusion criteria, of whom 145 (75.5%) underwent a complete medical investigation by the first author (T.K.) at a local hospital (Figure 1 ).
Clinical and laboratory investigations
Clinical and laboratory data recorded at the time of biopsy were obtained from the NKBR and included age, gender, body weight, height, body mass index (BMI), blood pressure (BP), serum creatinine, proteinuria (recorded as urinary protein excretion per 24 h), serum albumin and haematuria (urinary dipstick). eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [23] . All serum creatinine levels were reduced by 5% to standardize them to isotope dilution mass spectrophotometry-traceable levels [24] .
At the follow-up medical examination the following data were recorded: responsible physician during the follow-up period (none/primary physician/nephrologist), antihypertensive treatment [any/use of renin-angiotensin-aldosterone system (RAAS) blockade], body weight, height, BMI, BP, serum
creatinine (mmol/L), urinary albumin:creatinine ratio (UACR), haematuria (urinary dipstick), smoking status, history of preeclampsia or tonsillectomy and use of omega-3 fatty acids. eGFR was again calculated using the CKD-EPI formula.
Histopathological parameters
Kidney biopsy tissue from a total of 123 (85%) patients was available for re-examination, which was done by one pathologist (A.M.) and reviewed by an experienced nephropathologist (S.L.) at Haukeland University Hospital. The re-examination was done using the MEST scoring system (Oxford classification) for IgAN containing four independent prognostic factors for renal outcome: mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental glomerulosclerosis (S) and tubular atrophy/ interstitial fibrosis (T) [25] . We also investigated the predictive value of crescents. In the cases where kidney biopsy tissue was not available for re-examination, we examined the prognostic importance of the following histopathological parameters that had been routinely recorded in the NKBR: vascular changes (presence of arteriosclerosis or arteriolosclerosis), interstitial fibrosis (presence/absence), tubular atrophy (presence/absence) and segmental glomerulosclerosis (presence/absence).
Study endpoints
The observation period was defined as the period between the diagnostic kidney biopsy and the date of the follow-up examination. The primary endpoints in the present study were !50% reduction of GFR or ESRD and clinical remission (eGFR !60 mL/min/1.73 m 2 , absence of haematuria and microalbuminuria and BP <140/90 mmHg at follow-up). Secondary endpoints were UACR >30 mg/mmol creatinine, eGFR <45 mL/ min/1.73 m 2 , elevated BP !140/90 mmHg and change in eGFR (DeGFR) per year from biopsy to follow-up examination.
Statistical analysis
Categorical variables are presented as frequencies and percentages, continuous variables are expressed as mean 6 SD when normally distributed and as median with interquartile range (IQR) when not normally distributed. For tests of statistical differences, Fisher's exact and chi-squared tests were used for categorical variables, t-tests for normally distributed variables and the Mann-Whitney U test for variables that were not normally distributed. The Kaplan-Meier method was used to illustrate the risk of a !50% decrease in eGFR; the time point for this event to occur was estimated based on serial measurements of eGFR during follow-up and log-rank tests were used for tests of significance. Cox regression with univariate and multivariate analyses was used to investigate risk factors of endpoints. All tests were two-tailed, and P-values <0.05 were considered statistically significant. SPSS for Windows version 23 (IBM, Armonk, NY, USA) was used for statistical analyses.
R E S U L T S

Clinical and histological findings at biopsy
A total of 145 patients were included in the final analyses and their characteristics are shown in Table 1 . The mean age at the time of biopsy was 30.1 6 11.2 years and 73.8% were male. The median proteinuria was 0.3 (IQR 0-0.5) g/24 h and 37 . In the histopathological examination, mesangial hypercellularity in >50% of glomeruli (M1) was found in 15 (12.3%) patients, endocapillary proliferation (E1) was detected in 13 (10.7%) patients and segmental glomerulosclerosis (S1) was observed in 29 (23.8%) patients. All biopsies were scored as T0 (tubular atrophy in <25% of the cortical area) and 59 patients (48.4%) had a total absence of tubular atrophy. Crescents were found in 10 patients (6.9%).
Further details are given in Table 1 , which also shows that patients with proteinuria <0.2 g/24 h and >0.2 but <1 g/24 h had the same characteristics.
Follow-up and treatment
The median duration of follow-up was 22 (IQR 19-25) years. A total of 74 patients (51.0%) reported that they did not have any regular medical follow-up, 39 patients (26.9%) were followed regularly by a primary care physician and 32 patients (22.1%) were followed by a nephrologist. None of the patients had received steroids or other immunosuppressive medication during follow-up. A total of 13 patients (9.0%) reported daily intake of omega-3 fatty acids, and 12 patients (8.3%) had undergone tonsillectomy. A total of 60 (42.6%) patients received antihypertensive treatment; the majority of these (93.3%) were treated with RAAS blockade. Of interest, 37.8% of the women reported that they had been diagnosed with pre-eclampsia in at least one pregnancy. Overall, 22.8% reported daily smoking.
Primary outcomes
During follow-up, 27 patients (18.6%) developed a !50% decline in eGFR and 4 of these patients (2.8%) had progressed to ESRD-chronic dialysis treatment or kidney transplantation ( Table 2 ). The mean duration from biopsy to a !50% decrease in eGFR ranged from 6.5 to 25.2 years, with a mean of 17.3 6 5.1 years. Cumulative risks of a !50% decrease in eGFR were 2.1% after 10 years, 4.1% after 15 years, 13.9% after 20 years and (Figure 2A ). Baseline proteinuria (<0.2 g/ 24 h versus >0.2 but <1.0 g/24 h) did not predict a !50% decrease in eGFR (Table 2 and Figure 2B ). As shown in Table 3 , none of the investigated baseline clinical and histopathological variables differed significantly between patients with and without a !50% decrease in eGFR or ESRD, but obesity and elevated systolic and diastolic BP showed non-significant trends towards more progressive disease.
Clinical Table 2 ). Both systolic and diastolic BP were significantly higher at baseline in nonremitting patients (P ¼ 0.01 and P ¼ 0.04; Table 3 ), while younger age at the time of biopsy was non-significantly associated with remission (P ¼ 0.06). The presence of segmental sclerosis was non-significantly more frequently observed in nonremitting patients (P ¼ 0.06).
Neither clinical nor histopathological variables according to the MEST score predicted renal outcome in our multivariate regression analysis, although a non-significant trend of higher levels of baseline proteinuria and elevated diastolic BP and the presence of segmental sclerosis (S) were seen (P ¼ 0.09). (data not shown). There were no differences between patients with an absence of tubular changes and minor tubular changes (1-25%) according to primary endpoints. Crescents did not predict an unfavourable renal outcome in our cohort. In the cases where kidney biopsy tissue was not available for re-examination, we analysed the predictive effect of histopathological variables inherit in the NKBR, including segmental glomerulosclerosis (S) and tubular atrophy (T), with similar definitions as used in the Oxford classification. None of these factors associated with progressive disease in our study.
Secondary outcomes
UACR !30 mg/mmol was present in 24 (16.6%) patients at follow-up (18 had a UACR of 30-100 mg/mmol and 6 had a UACR !100 mg/mmol); 70.8% of these patients were treated with RAAS blockade. The baseline characteristics of these 24 albuminuric patients were fairly similar to those of nonalbuminuric patients, but albuminuric patients had significantly higher diastolic BP and non-significantly more proteinuria at the time of biopsy (Table 3) .
In all, 21 patients (14.5%) had an eGFR <45 mL/min/1.73 m 2 at follow-up. There were no significant differences in this group according to baseline proteinuria more than or less than 0.2 g/24 h ( Table 2 ). Cumulative risks of eGFR <45 mL/min/ 1.73 m 2 were 2.1% after 10 years, 5.5% after 15 years, 12.4% after 20 years and 18.4% after 25 years. None of the investigated baseline variables differed significantly between patients with or without eGFR <45 mL/min/1.73 m 2 . In total, 63 (44.7%) patients had BP exceeding 140/90 mmHg at follow-up and 31 of these (21.9%) had normal BP at the time of biopsy. Of the patients with BP !140/90 mmHg at follow-up, 8 were treated with RAAS blockade whereas 23 were untreated. Of note, five patients with BP !140/90 mmHg and micro-albumuria or more severe albuminuria had neither antihypertensive medication nor regular medical follow-up. Baseline BP (<140/90 mmHg versus !140/90) did not predict a !50% decrease in eGFR at follow-up ( Figure 2C ). Table 4 shows DeGFR per year between renal biopsy and follow-up according to urinalysis at follow-up. Albuminuria at the time of follow-up was significantly associated with DeGFR during the study period. Conversely, persisting isolated microscopic haematuria without albuminuria was not associated with a loss of renal function during follow-up. 
D I S C U S S I O N
The main finding in the present study is that the very longterm prognosis in patients with IgAN presenting with eGFR !60 mL/min/1.73 m 2 and proteinuria <1 g/24 h is variable. At 25 years of follow-up, close to 25% of patients had deteriorating renal function with a decrease in eGFR of !50% or progression to ESRD. On the other hand, approximately onethird of patients had full clinical remission with normal eGFR, BP and urine. Our study demonstrates that an extended follow-up period is needed when assessing prognosis in this group of patients; the mean duration from renal biopsy to a !50% decrease in eGFR was 17.3 6 5.1 years in our cohort and it is of interest that four patients (2.8%) had an eGFR of 45-60 mL/min/1.73 m 2 and thus are at high risk of future progression.
Considering that renal function deterioration is typically very slow, with the GFR often decreasing by as little as 1-3 mL/ min/1.73 m 2 per year, there is naturally a big discrepancy between the number of patients with a !50% decrease in eGFR and the number with ESRD. Given the fact that mean age at follow-up was only 52 years in this cohort, and thus had a mean remaining expected lifespan of at least 30 years, we believe that a large number of patients with a !50% decrease in eGFR eventually will progress to ESRD.
To our knowledge, seven previous studies have reported the prognosis of patients with IgAN presenting with low-grade proteinuria and normal renal function (Table 5 ) [11, [16] [17] [18] [19] [20] . Five of these were based on Asian cohorts [16] [17] [18] [19] [20] . The major difference between the current study and these seven other investigations is the median length of follow-up, which ranged between 4.3 and 10.3 years in previous studies as compared to 22 years in the current work. Direct comparisons of outcome in these a DeGFR/year, the annual rate of decline in eGFR, determined as the difference between the follow-up and baseline eGFR values, with this value divided by the time interval from renal biopsy to follow-up examination.
b ESRD/RRT patients excluded.
studies are complicated by different definitions of endpoints and different lengths of follow-up. However, a substantial risk of progressive loss of renal function is generally described, supporting the current findings. One particular exception is a Spanish study [11] that reported an excellent prognosis with no cases of ESRD and only 3.5% of patients experiencing a >50% increase in serum creatinine. Whether the prognosis in the Spanish cohort will remain excellent or whether more cases of renal impairment will appear with increasing length of follow-up is uncertain. In this regard, it should be noted that in the present results the cumulative risk of a !50% decrease in eGFR increased from 2.1% at 10 years to 24.7% at 25 years of follow-up (Figure 2A ). An interesting observation arising from the present study is that the outcome of patients could not be predicted by clinical or histopathological variables at the time of the diagnostic kidney biopsy. Neither proteinuria, eGFR nor histopathological lesions were associated with risk of progression. In general, recent prognostic studies in IgAN have found improved prognostic capacity by applying the novel Oxford/MEST classification [13] , although whether it offers an increased value in predicting mild clinical IgAN patients seems uncertain. We could not detect an improved value for predicting renal outcome according to histopathological findings with application of the MEST score in our cohort. In the study by Gutierrez et al., [11] the only study of clinically mild IgAN patients utilizing the MEST score, segmental sclerosis (S) was the only lesion significantly associated with a >50% increase in serum creatinine by multivariate analysis. In the recent European Validation Study of the Oxford Classification of IgA Nephropathy (VALIGA), a subgroup analysis of 219 patients with minimal proteinuria at presentation demonstrated that mesangial hypercellularity (M) and endocapillary proliferation (E) were significant predictors of an increase in proteinuria up to values of !1 g/24 h and !2 g/24 h during the subsequent follow-up. However, none of the MEST score parameters were predictive of the primary endpoint, a !50% decrease in eGFR or progression to ESRD in multivariate analysis [14] . In accordance with 
this, the MEST score might seem to be a less prominent predictor of progressive disease in IgAN patients with preserved renal function and initial proteinuria <0.5 g/24 h than in patients with a higher risk of progression. Histopathological characteristics in low-risk IgAN should be evaluated further in future studies, but this could be difficult due to an abandoned liberal biopsy practice for these patients in the USA and most European countries. Albuminuria at the time of follow-up was, in line with current literature [6, 23, 24] , significantly associated with a greater decrease in eGFR. Conversely, persisting microscopic haematuria without albuminuria was not associated with a decrease in eGFR (Table 4 ). In the current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for IgAN, angiotensinconverting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) treatment is recommended in patients with proteinuria !1 g/24 h and suggested in patients with proteinuria of 0.5-1.0 g/24 h. Our finding that lower degrees of albuminuria down to and including microalbuminuria is associated with significantly deteriorating kidney function indicates that RAAS blocking agents probably should be suggested for all patients with IgAN and abnormal urinary albumin excretion. It should be noted, however, that we measured urinary albumin excretion solely at the last follow-up visit and that it is uncertain whether this measurement reflected a time-averaged urinary albumin excretion.
Previously we had no systematic data on how and to what extent patients with assumed benign IgAN were followed up in the Norwegian health care system. Interestingly, 51% had no regular medical follow-up, and among the other 49%, 27% were followed by their primary care physician and 22% by a nephrologist. As illustrated in Figure 3 , patients followed by nephrologists were mainly those with progressive disease. Unfortunately, seven patients (4.8%) had progressive disease with proteinuria and high BP and no treatment or medical follow-up. These findings underscore the importance of regular follow-up and adequate BP treatment, even among patients with assumed benign IgAN.
In current practice, few nephrological departments in Europe have maintained the policy of performing renal biopsy in patients with a clinical picture of low-grade proteinuria (<1 g/24 h), haematuria and normal-range eGFR [11, 15] . Thus, until reliable non-invasive diagnostic methods for IgAN are developed, many patients similar to those in the present study will not be diagnosed with IgAN. The reasons for not diagnosing cases of presumed mild IgAN are the previous assumption of excellent renal prognosis and the lack of therapeutic options beyond BP-lowering drugs, including RAAS blockers [25] [26] [27] [28] [29] . From a prognostic point of view, based on the results of the current and previous findings, one could argue for a more liberal biopsy policy. However, we will argue for a more pragmatic approach; patients with low-grade proteinuria and haematuria should be followed clinically with liberal indication for albuminuria-lowering antihypertensive treatment, and those showing signs of increasing proteinuria or progressive renal failure can be biopsied later in the disease course.
As noted previously, there is no well-documented treatment for IgAN patients with low-grade proteinuria. KDIGO suggests the use of an ACE-I or ARB in patients with proteinuria of 0.5-1.0 g/24 h and, with a few unfortunate exceptions, the majority of patients in our cohort with this level of albuminuria received such treatment. In fact, 82% of patients progressing to a !50% decrease in eGFR were treated with a RAAS blocking agent. Thus undertreatment with anti-proteinuric agents according to current guidelines cannot be an important explanatory factor for the findings in the present study. However, it is reasonable to speculate whether a larger fraction of patients having albuminuria <0.5 g/24 h would have benefitted from treatment with an ACE-I or ARB. Unfortunately, up to 50% of the patients had a BP !140/90 mmHg at the follow-up investigation. However, it should be mentioned that BP measurements were performed only at one clinical examination, and it is uncertain whether repeated measurements or ambulatory measurements would show the same degree of inadequately treated hypertension. Of interest, a substantial fraction (20.4%) of patients receiving RAAS blockers still had BP !140/90 mmHg. Our findings indicate that a larger number of patients should have received BP treatment and that many who were treated should have been treated more aggressively.
Of interest, 14 of a total of 78 pregnancies (18%) from women in this cohort were complicated with pre-eclampsia; this is in contrast to a reported prevalence of 3-4% in the general population [30, 31] . The majority of these women were diagnosed with IgAN due to persisting urine abnormalities postpartum. Thus the onset of pre-eclampsia unmasked the presence of unrecognized IgAN, which also was a risk factor for pre-eclampsia in these patients. These interesting findings underscore the view that IgAN cannot be considered an insignificant condition even when patients are having low-grade proteinuria.
We are aware that our study has some limitations. First, 47 (24.5%) eligible patients did not participate, inducing a possibility of selection bias in our study. However, the outcomes of FIGURE 3: Level of follow-up according to DeGFR/year and albuminuria at follow-up. Logarithmic scale on the x-axis and a linear scale on the y-axis. DeGFR/year, the annual rate of decline in eGFR, determined as the difference between the follow-up and baseline eGFR values, with this value divided by the time interval from renal biopsy to follow-up examination.
